Greenwich LifeSciences, Inc. — Q1 2023 Form 10-Q
Business context and period: Clinical-stage biopharmaceutical company developing GLSI-100 (GP2 plus GM-CSF) to prevent breast cancer recurrence. The unaudited quarter ended March 31, 2023; comparisons are with Q1 2022 unless noted. The company had no revenue and was conducting its Phase III Flamingo-01 trial.
Financial highlights
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development | $1.83 million | $1.66 million; up 10% |
| General and administrative | $413,175 | $328,382; up 26% |
| Total operating expenses | $2.24 million | $1.99 million |
| Operating loss | $2.24 million | $1.99 million |
| Interest income | $116,180 | $19,575 |
| Net loss | $2.12 million | $1.97 million |
| Basic and diluted loss per share | $0.17 | $0.15 |
| Cash used in operating activities | $1.56 million | $1.95 million |
At March 31, 2023, cash was $11.91 million, versus $13.47 million at year-end 2022. Total assets were $11.92 million; total liabilities were $235,575, including $220,845 in accounts payable and accrued interest to the Henry M. Jackson Foundation (HJF). Stockholders’ equity was $11.68 million. The filing reports no material contractual obligations beyond employment and shareholder agreements, the HJF license, and clinical-trial and manufacturing obligations. No investing cash flows or Q1 2023 stock repurchases were reported. The filing does not provide a margin measure or a specific cash-runway estimate.
Changes, outlook, risks, and unusual items
- Net loss increased about 8% year over year as research and development and general and administrative expenses rose; management attributed the R&D increase mainly to cash compensation, clinical, and manufacturing expenses.
- Stock-based compensation was $594,522, compared with $165,267 in Q1 2022. It was a significant non-cash adjustment in the operating cash-flow reconciliation.
- The company expects continued losses and significant expenses as it develops its pipeline and conducts clinical trials. Management says additional capital will be required for long-term operating needs and anticipates seeking equity and/or debt financing; success in raising capital is not assured.
- Flamingo-01 is a Phase III trial evaluating GLSI-100 in specified HER2-positive patients after trastuzumab-based treatment. The filing gives no financial guidance or trial timetable in this text.
- The company cites risks including clinical development and financing uncertainty, dependence on third-party manufacturers, and the possibility that actual results differ materially from forward-looking statements. It reported no material legal proceedings and no material change to the risk factors in its 2022 Form 10-K.
- Disclosure controls were deemed ineffective at March 31, 2023 due to material weaknesses: inadequate segregation of duties because of limited personnel, and insufficient written accounting, IT, financial-reporting, and recordkeeping policies. Management said it was developing a remediation plan.
- The board-authorized stock repurchase program ran through March 31, 2023. By that date, approximately 519,828 shares had been repurchased and canceled for an aggregate cost of about $7.54 million; none were repurchased in Q1 2023.
Investor verification points
- Review Flamingo-01 enrollment, execution, costs, and milestones, and assess how clinical results may affect funding needs.
- Track cash burn and financing plans against the $11.91 million quarter-end cash balance; the filing does not specify runway.
- Check progress and evidence of remediation of the disclosed internal-control material weaknesses.
- Confirm the status and terms of HJF license obligations and clinical-trial and manufacturing commitments.
- Verify subsequent share count and any warrant or equity-plan dilution; 12,848,165 common shares were outstanding at March 31, 2023, and 20,174 warrants were outstanding.